drugset
drugset / Trial / NCT04127058

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

NCT04127058 ↗

Phase 1 Completed 12 enrolled Vanda Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center open-label study to be conducted in the United States in subjects with bipolar I disorder or schizophrenia.

Timeline

Start
2019-10-07
Primary completion
2019-11-27
Completion
2019-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 12 mg Oral
Subject Iloperidone Small molecule 24 mg Oral

Indications

bipolar I disorder schizophrenia